These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 15805299

  • 1. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2.
    Rahaman SO, Vogelbaum MA, Haque SJ.
    Cancer Res; 2005 Apr 01; 65(7):2956-63. PubMed ID: 15805299
    [Abstract] [Full Text] [Related]

  • 2. PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells.
    Ghosh MK, Sharma P, Harbor PC, Rahaman SO, Haque SJ.
    Oncogene; 2005 Nov 10; 24(49):7290-300. PubMed ID: 16007122
    [Abstract] [Full Text] [Related]

  • 3. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells.
    Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ.
    Cancer Res; 2002 Feb 15; 62(4):1103-9. PubMed ID: 11861389
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways.
    Leu CM, Wong FH, Chang C, Huang SF, Hu CP.
    Oncogene; 2003 Oct 30; 22(49):7809-18. PubMed ID: 14586407
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells.
    Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ.
    Oncogene; 2002 Dec 05; 21(55):8404-13. PubMed ID: 12466961
    [Abstract] [Full Text] [Related]

  • 6. Functional characterization of IL-13 receptor alpha2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression.
    David MD, Bertoglio J, Pierre J.
    Oncogene; 2003 May 29; 22(22):3386-94. PubMed ID: 12776189
    [Abstract] [Full Text] [Related]

  • 7. IL-4-dependent induction of BCL-2 and BCL-X(L)IN activated T lymphocytes through a STAT6- and pi 3-kinase-independent pathway.
    Aronica MA, Goenka S, Boothby M.
    Cytokine; 2000 Jun 29; 12(6):578-87. PubMed ID: 10843732
    [Abstract] [Full Text] [Related]

  • 8. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways.
    O'Farrell AM, Liu Y, Moore KW, Mui AL.
    EMBO J; 1998 Feb 16; 17(4):1006-18. PubMed ID: 9463379
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors.
    Karni R, Jove R, Levitzki A.
    Oncogene; 1999 Aug 19; 18(33):4654-62. PubMed ID: 10467412
    [Abstract] [Full Text] [Related]

  • 10. Augmentation of signal transducer and activation of transcription (STAT)6 and STAT3 expression in stimulated B and T cells.
    Arinobu Y, Sugimoto R, Akaiwa M, Arima K, Otsuka T, Hamasaki N, Izuhara K.
    Biochem Biophys Res Commun; 2000 Oct 22; 277(2):317-24. PubMed ID: 11032724
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells.
    Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R.
    Int Immunopharmacol; 2004 May 22; 4(5):679-91. PubMed ID: 15120652
    [Abstract] [Full Text] [Related]

  • 12. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
    Jourdan M, De Vos J, Mechti N, Klein B.
    Cell Death Differ; 2000 Dec 22; 7(12):1244-52. PubMed ID: 11175262
    [Abstract] [Full Text] [Related]

  • 13. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells.
    Huang M, Page C, Reynolds RK, Lin J.
    Gynecol Oncol; 2000 Oct 22; 79(1):67-73. PubMed ID: 11006034
    [Abstract] [Full Text] [Related]

  • 14. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B.
    Oncogene; 2004 Apr 29; 23(20):3530-40. PubMed ID: 15077178
    [Abstract] [Full Text] [Related]

  • 15. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.
    Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H.
    Oncogene; 2002 Oct 10; 21(46):7001-10. PubMed ID: 12370822
    [Abstract] [Full Text] [Related]

  • 16. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
    Kawakami K, Kawakami M, Liu Q, Puri RK.
    Int J Radiat Oncol Biol Phys; 2005 Sep 01; 63(1):230-7. PubMed ID: 16111594
    [Abstract] [Full Text] [Related]

  • 17. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis.
    Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM.
    Gastroenterology; 2002 Dec 01; 123(6):2052-63. PubMed ID: 12454861
    [Abstract] [Full Text] [Related]

  • 18. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma.
    Campbell CL, Jiang Z, Savarese DM, Savarese TM.
    Am J Pathol; 2001 Jan 01; 158(1):25-32. PubMed ID: 11141475
    [Abstract] [Full Text] [Related]

  • 19. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ.
    Clin Cancer Res; 2005 Sep 01; 11(17):6333-41. PubMed ID: 16144938
    [Abstract] [Full Text] [Related]

  • 20. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
    Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY.
    Clin Cancer Res; 1999 May 01; 5(5):985-90. PubMed ID: 10353730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.